US009085577B2 (12) United States Patent (10) Patent No.: US 9,085,577 B2 Cid-Nunez et al. (45) Date of Patent: Jul. 21, 2015 (54) 7-ARYL-1,2,4-TRIAZOLO4,3-APYRIDINE (58) Field of Classification Search DERVATIVES AND THEIR USE AS POSITIVE CPC A61 K9/2018; A61 K9/0014: A61 K9/0019; ALLOSTERIC MODULATORS OF MIGLUR2 A61 K9/0095; A61 K9/06; A61 K9/2009: RECEPTORS A61 K9/2059; A61K 45/06; A61K 31/437; A61K 31/444; A61K 31/4545; A61 K31/5377: (71) Applicants:JANSSEN PHARMACEUTICALS, A61K 47/06; A61K 47/10; A61 K47/26: INC. Titusville, NJ (US); ADDEX A61K 47/38 PHARMA, S.A., Geneva (CH) USPC .......................................................... 514/303 See application file for complete search history. (72) Inventors: Jose Maria Cid-Nunez, Toledo (ES); Ana Isabel De Lucas Olivares, Toledo (ES); Andres Avelino Trabanco-Suarez, (56) References Cited Toledo (ES); Gregor James U.S. PATENT DOCUMENTS MacDonald, Beerse (BE) 4,051,244. A 9, 1977 Matiioda et al. (73) Assignees: Janssen Pharmaceuticals, Inc., 4,066,651 A 1/1978 Brittain et al. Titusville, NJ (US); Addex Pharma, (Continued) S.A., Geneva (CH) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 BE 841390 11, 1976 U.S.C. 154(b) by 0 days. CA 1019323 1Of 1977 (Continued) (21) Appl. No.: 14/215,462 OTHER PUBLICATIONS (22) Filed: Mar 17, 2014 Dwyer, J Molecular Psychiatry, vol. 1 (15), 2013, p. 1-4.* (65) Prior Publication Data (Continued) US 2014/O2OO2O8 A1 Jul. 17, 2014 Primary Examiner — D M Seaman Related U.S. Application Data (74) Attorney, Agent, or Firm — Baker & Hostetler LLP (63) Continuation of application No. 13/319.568, filed as application No. PCT/EP2010/002909 on May 11, (57) ABSTRACT 2010, now Pat. No. 8,716,480. The present invention relates to novel triazolo 4,3-alpyridine derivatives of Formula (I) wherein all radicals are as defined (30) Foreign Application Priority Data in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate May 12, 2009 (EP) ..................................... O916OO64 receptor subtype 2 (“mCluR2), which are useful for the treatment or prevention of neurological and psychiatric dis (51) Int. Cl. orders associated with glutamate dysfunction and diseases in A6 IK 47/38 (2006.01) which the mGluR2 subtype of metabotropic receptors is CO7D 47L/04 (2006.01) involved. The invention is also directed to pharmaceutical A6 IK 45/06 (2006.01) compositions comprising Such compounds, to processes to A6 IK9/20 (2006.01) prepare such compounds and compositions, and to the use of A6 IK3I/437 (2006.01) Such compounds for the prevention or treatment of neurologi A6 IK3I/444 (2006.01) cal and psychiatric disorders and diseases in which mGluR2 A6 IK3 L/4545 (2006.01) is involved. A 6LX3/5377 (2006.01) A6 IK9/00 (2006.01) A6 IK 47/06 (2006.01) (I) (Continued) (52) U.S. Cl. CPC ............ C07D 471/04 (2013.01); A61 K9/0014 (2013.01); A61 K9/0019 (2013.01); A61 K 9/0095 (2013.01); A61 K9/06 (2013.01); A61 K 9/2009 (2013.01); A61 K9/2018 (2013.01); A61 K9/2059 (2013.01); A61 K3I/437 (2013.01); A61 K3I/444 (2013.01); A61 K 31/4545 (2013.01); A61K3I/5377 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K47/10 (2013.01); A61K 47/26 (2013.01); A61K47/38 (2013.01) 15 Claims, No Drawings US 9,085,577 B2 Page 2 (51) Int. Cl. 6,333,428 B1 12/2001 Nakazato et al. A6 IK 47/10 (2006.01) 6,358,975 B1 29: s l 6,361,571 B1 3/2002 Goettel et al. A6 IK 47/26 (2006.01) 6,403,588 B1 6/2002 Hayakawa et al. A6 IK9/06 (2006.01) 6,407,094 B1 6/2002 Adam et al. 6.432,958 B1 8/2002 He 6,433,014 B1 8/2002 Acher et al. (56) References Cited 6,455,528 B1 9/2002 Adachi et al. 6,465,484 B1 10/2002 Bilodeau et al. U.S. PATENT DOCUMENTS 6,472,392 B1 10/2002 Starck et al. 6.479,436 B1 1 1/2002 Otten et al. 2:3: A 38. WS al 6,498,180 B1 12/2002 Collado Cano et al. 4,256,738 A 3/1981 Woitun et al. 835, 38 TS a 4,358,453 A 1 1/1982 Bristol et al. 6,586.441 B2 7/2003 Borroni et al. 4.550,166 A 10/1985 Moran et al. 6,607,563 B2 8/2003 Ohashi et al. 4.866,074 A 9/1989 Spada et al. 6,664,250 B2 12/2003 Atwal et al. 4,898,654. A 2/1990 Toda et al. 6,670,307 B2 12/2003 Schnatterer et al. 2. A 12 go East al. 6,835,726 B2 12/2004 Cushing et al. 5,130,442 A 7/1992 Meisel et al. 7.E. E: 58 RY, 5,175,157 A 12/1992 Psiorz et al. 757.807 B2 8, 2009 Lietal 5,204,198 A 4, 1993 Bugner et al. 7.579360 B2 8/2009 Lietal. 5,236.917 A 8/1993 Dunlap et al. 7,700,593 B2 4/2010 Chakrabarti et al. 5,254,543 A 10/1993 Hanko et al. 7,879.837 B2 2/2011 Hayashi et al. 5,260,293 A 1 1/1993 Baker et al. 7,960,563 B2 6/2011 Johnson et al. 39: A ! E: Rita 7.977,325 B2 7/2011 Schwede et al. 5,356,911. A 10/1994 Muller-Gillemann et al. 5.8 R: 6585 N. a 5,366,981 A 11/1994 Vecchietti et al. 8,395,493 B2 3/2013 Bolea et al. 5,371,074 A 12/1994 Dunlap et al. 2002fOOO9713 A1 1/2002 Miller et al. 5,374,513 A 12/1994. Ohzeki et al. 2002/0022636 A1 2/2002 Li et al. 5,378,720 A 1/1995 Hlasta et al. 2002/0O28813 A1 3/2002 Jackson et al. 5,407,948 A 4/1995 Fey et al. 2002/0041880 A1 4/2002 Defeo-Jones et al. 5,418,243 A 5/1995 Angerbauer et al. 2002.0137770 A1 9, 2002 Nara et al. 5,424435 A 6/1995 Hani et al. 2002/0147362 A1 10, 2002 Kozikowski et al. 5,473,077. A 12, 1995 Monnet al. 2002.01933.67 A1 12/2002 Adam et al. 5,498,774. A 3/1996 Mitsudera et al. 2002fO198197 A1 12/2002 Adam et al. 5,500.420 A 3, 1996 Maiese 2003/0055085 A1 3/2003 Wagenen et al. 5,512,576 A 4, 1996 Desai et al. 2003/01095.04 A1 6/2003 Brotchie et al. 5,532,242 A 7/1996 Cliffe 2003. O130264 A1 7, 2003 Jaen 5,596,012 A 1/1997 Dunlap et al. 2003/0134902 A1 7/2003 Nakazato et al. 5,602,145 A 2, 1997 Samanen 2003. O1581.55 A1 8, 2003 Hori et al. 5,650,422 A 7/1997 Dunlap et al. 2003/01628O2 A1 8/2003 Guo et al. 5,654,307 A 8, 1997 Bridges et al. 2003/0166639 A1 9, 2003 Adam et al. 5,675,013. A 10/1997 Hani et al. 2003/0171380 A1 9, 2003 Arvanitis et al. 5,710,274. A 1/1998 Yuan et al. 2003/01996.92 A1 10/2003 Biediger et al. 5,723.463 A 3/1998 Hofgen et al. 2003/0207882 A1 11/2003 Stocker et al. CE A vision etal 2003/0207916 A1 1 1/2003 Cheng et al. wW 2004/0006114 A1 1/2004 Coleman et al. 5,814,645. A 9, 1998 Kanellakopulos et al. 2004/0034040 A1 2/2004 Eggenweiler et al. 5,855,654. A 1/1999 Willingham et al. 2004/0043388 A1 3/2004 Come et al. 5,859,020 A 1/1999 Preuss et al. 2004/004903.2 A1 3/2004 Charrier et al. 5,869,428 A 2, 1999 Morishima et al. 2004/0053914 A1 3/2004 Gharagozlooet al. 3:13; A 2.92. Persial 2004/0063955 A1 4/2004 Biediger et al. 5.948,911- 44 A 9/1999 Pamukcu et al. 58,867.2004/OO77599 A1A 4, 55A2004 Curof Enet al. 5,958,931 A 9/1999 Adam et al. 2004/0101833 A1 5/2004 LaZdunski et al. 6,013,672 A 1/2000 Yeet al. 2004/0102521 A1 5/2004 Collado Cano et al. 6,022,869 A 2/2000 Faull 2004/0106791 A1 6/2004 Yoakim et al. 6,054,588 A 4/2000 Adam et al. 2004/01 16489 A1 6/2004 Massey et al. 6,093,718. A 7/2000 Waterson et al. 2004/O127936 A1 7/2004 Salahieh et al. 6,100,268 A 8/2000 Van Lommen et al. 2004/O132723 A1 7/2004 Yoakim et al. 6,103,475 A 8/2000 Burnett, Jr. et al. 2004/0138204 A1 7/2004 Harrington, Jr. 6,107,342 A 8/2000 Adam et al. 2004/O138238 A1 7/2004 Dhanoa et al. 6,110,920 A 8/2000 Rochus et al. 2004O167123 A1 8, 2004 Prati et al. 6,121,278 A 9/2000 Jackson et al. 2004/0176385 A1 9, 2004 NuSS et al. 6,130,217 A 10/2000 Arnold et al. 2004/0204448 A1 10, 2004 Muller et al. 6,133,271. A 10/2000 Pamukcu et al. 2004/0220222 A1 1 1/2004 Galley et al.